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Objective: To evaluate 18F-ﬂuorodeoxyglucose (18F-FDG) uptake on positron emission
tomography–computed tomography (PET–CT) and serum levels of different cytokines and
matrix metalloproteinases (MMPs) in patients with Takayasu arteritis (TA) and associations
with disease activity.
Methods: Serum levels of tumor necrosis factor- (TNF-), interleukin (IL)-2, IL-6, IL-8, IL-
12,  IL-18, MMP-3 and MMP-9 were measured in 36 TA patients and 36 controls. Maximum
standard uptake value (SUVmax) of 18F-FDG in arterial walls was determined by PET–CT scans.
TA  patients were classiﬁed as active disease, inactive disease and possible active disease.
Results: Serum IL-6 and MMP-3 levels were higher in TA patients than in controls (p < 0.001).
Serum IL-6 was higher in patients with active disease and in patients with possible active
disease than in inactive disease (p < 0.0001). Patients with active disease had higher serum
TNF  levels than patients with inactive disease (p = 0.049) while patients with possible active
disease presented higher IL-18 levels than patients with inactive disease (p = 0.046). Patients
with active disease had higher SUVmax values than those with inactive disease (p = 0.042). By
receiver operating characteristic (ROC) curve SUVmax was predictive of active disease in TA
and  values ≥1.3 were associated with disease activity (p = 0.039). Serum TNF- levels were
higher in patients with SUVmax ≥ 1.3 than <1.3 (p = 0.045) and controls (p = 0.012). Serum IL-6
levels were higher in patients with SUVmax ≥ 1.3 than in controls (p < 0.001). No differences
regarding other biomarkers were found between TA patients and controls.
Conclusions: Higher serum IL-6 and TNF levels as well as higher 18F-FDG uptake in arterialwall are associated with active TA.© 2015 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
∗ Corresponding author.
E-mail: eisato@unifesp.br (E.I. Sato).
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Tomograﬁa  por  emissão  de  pósitrons  com  18F-ﬂuordesoxiglicose  e
citocinas  séricas  e  metaloproteinases  da  matriz  na  avaliac¸ão  da  atividade
da  doenc¸a na  arterite  de  Takayasu
Palavras-chave:
Citocinas
Metaloproteinases da matriz
Tomograﬁa computadorizada
Arterite de Takayasu
r  e  s  u  m  o
Objetivo: Avaliar a captac¸ão de 18F-ﬂuordesoxiglicose (18F-FDG) na tomograﬁa por emissão
de  pósitrons–tomograﬁa computadorizada (PET–CT) e os níveis séricos de diferentes citoci-
nas e da metaloproteinases da matriz (MMP) em pacientes com arterite de Takayasu (AT) e
associac¸ões  com a atividade da doenc¸a.
Métodos: Foram mensurados os níveis séricos do fator de necrose tumoral- (TNF-), inter-
leucina (IL)-2, IL-6, IL-8, IL-12, IL-18, MMP-3 e MMP-9 em 36 pacientes com AT e 36 controles.
O  valor padronizado de captac¸ão máximo (SUVmax) de 18F-FDG nas paredes arteriais foi
determinado por exames de PET–CT. Os pacientes com AT foram classiﬁcados como tendo
doenc¸a  ativa, doenc¸a inativa e possível doenc¸a ativa.
Resultados: Os níveis séricos de IL-6 e MMP-3 foram mais altos em pacientes com AT do que
nos  controles (p < 0,001). Os níveis séricos de IL-6 eram mais elevados em pacientes com
doenc¸a  ativa e em pacientes com possível doenc¸a ativa do que naqueles com doenc¸a ina-
tiva  (p < 0,0001). Os pacientes com doenc¸a ativa apresentaram níveis séricos mais elevados
de  TNF- do que os pacientes com doenc¸a inativa (p = 0,049), enquanto os indivíduos com
possível doenc¸a ativa apresentaram maiores níveis séricos de IL-18 do que os pacientes
com  doenc¸a inativa (p = 0,046). Aqueles com doenc¸a ativa apresentaram maiores valores de
SUVmax do que aqueles com doenc¸a inativa (p = 0,042). De acordo com a curva ROC, o SUVmax
era capaz de predizer a doenc¸a ativa na AT e valores ≥1,3 estavam associados à atividade da
doenc¸a  (p = 0,039). Os níveis séricos de TNF- foram maiores em pacientes com SUVmax ≥ 1,3
do  que naqueles com valor <1,3 (p = 0,045) e controles (p = 0,012). Os níveis séricos de IL-6
foram  mais elevados em pacientes com SUVmax ≥ 1,3 do que nos controles (p < 0,001). Não
foram encontradas diferenc¸as em relac¸ão a outros biomarcadores entre pacientes com AT
e  controles.
Conclusões: Níveis séricos elevados de IL-6 e TNF-, bem como uma  maior captac¸ão de
18F-FDG na parede arterial, estão associados a AT ativa.
© 2015 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Takayasu arteritis (TA) is a primary systemic vasculitis of
unknown etiology that affects large arteries, mainly the aorta
and its main branches and less frequently pulmonary and
coronary arteries. The chronic granulomatous inﬂammation
occurs in all layers of the vessel wall and may lead to stenosis,
occlusion, dilation or aneurysm formation.1,2
Cell-mediated autoimmunity plays a key role in the patho-
genesis of TA. Immunohistochemical studies of the inﬁltrating
cells in the aortic tissue have shown mainly gamma-delta T-
cells, CD4+ and CD8+ T-cells, NK cells and macrophages.3 The
presence of granulomatous inﬂammation in the internal elas-
tic layer is the most characteristic pathologic ﬁnding of TA.
The inﬂammatory process begins in the vasa vasorum and it is
believed to be triggered by the activation of dendritic cells and
dendritic cell/T-cell interaction in the vascular microenviron-
ment of the adventitia of large arteries leading to the induction
of a Th1 response.4
The detection of vascular inﬂammation in TA patients is
a major challenge in clinical practice, since up to 60% of
asymptomatic patients developed new angiographic lesions
on sequential arteriographic evaluation, and 44% of patientsBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
considered to be in remission by clinical evaluation showed
histopathological evidence of active inﬂammation on surgical
specimens.1 Due to the evidence of progression of vascular
damage in asymptomatic TA patients, additional evaluation
is necessary to guide therapeutic decisions. Nevertheless, to
date there is no reliable surrogate parameter to detect subclini-
cal disease activity in TA patients. Potential biological markers
of inﬂammation and tissue degradation, such as cytokines
and metalloproteinases (MMPs) have been evaluated sepa-
rately in different studies but some results have not been
reproduced.5–7 Different imaging techniques have been used
to assess the extent of arterial involvement in TA, among them
18F-ﬂuorodeoxyglucose (18F-FDG) positron emission tomogra-
phy with computed tomography (PET–CT) scan can detect
active arterial wall inﬂammation. Some studies have been
promising8–10 whereas others have found conﬂicting results
with the use of PET–CT scans to evaluate disease activity in
TA.11,12
The aims of this study were to evaluate the intensity of
18F-FDG uptake on PET–CT scans on arterial walls and quan-
tify serum levels of interleukin-2 (IL-2), IL-6, IL-8, IL-12, IL-18,
tumor necrosis factor- (TNF-),  MMP-3 and MMP-9 in patients
with TA and controls as well as to evaluate possible associa-
tions with disease activity in TA.
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aterials  and  methods
atients  and  controls
atients under regular follow-up at the Vasculitis Unit of
he university hospital of Universidade Federal de São Paulo
Unifesp) or at private ofﬁces of rheumatologists who work at
nifesp were consecutively invited to participate in this cross-
ectional study. They underwent clinical, laboratorial and
maging evaluation within a 20-day period. Inclusion criteria
ere the fulﬁllment of the American College of Rheuma-
ology (ACR) classiﬁcation criteria for TA,13 age above 18
ears and the absence of malignancy, active infection and
regnancy. The control groups comprised laboratory controls
lab-controls) and PET–CT scan controls (PET-controls). The
ormer group included 36 age- and gender-matched subjects
ithout chronic inﬂammatory or infectious disease and the
atter group consisted of six healthy individuals who under-
ent a PET–CT scan, using the same protocol used by TA
atients. All subjects signed informed consent form approved
y the Institutional Ethics Committees from Unifesp and AC
amargo Hospital.
linical  and  laboratory  assessment
he clinical assessment of TA patients was performed by two
hysicians experienced in TA management (AWSS and HAM)
t routine medical visits. Disease activity was deﬁned whether
he onset or worsening of at least two of the following features
as present: (a) systemic features with no other identiﬁed
ause; (b) the onset of features of vascular ischemia or inﬂam-
ation, such as limb claudication, unequal or absent pulse,
ruit, vascular pain (carotidynia) or asymmetric blood pres-
ure; (c) elevated acute phase reactants including erythrocyte
edimentation rate (ESR); (d) development of new lesions in
reviously unaffected vascular territories on serial vascular
maging evaluation.1 TA patients presenting abnormal levels
f acute phase reactants (i.e. ESR ≥ 40 mm/h  and/or serum CRP
evels ≥ 10 mg/dL) without signs and symptoms of active TA or
ew angiographic lesions were considered a distinct subgroup
amed as possible active disease.
Blood samples were collected from patients and lab-
ontrols for cytokines, MMPs, ESR (Westergren) and CRP
easurements. Serum samples were separated and stored
t −70 ◦C until tests were performed. The enzyme-linked
mmunosorbent assay (ELISA) technique was used to quantify
RP (Diagnostics Systems Laboratories, EUA), IL-18 (Kit Med
 Biologic Lab Co, Japan), MMP-3 and MMP-9 (R&D Systems,
UA). All tests were performed in duplicate. The measurement
f IL-2, IL-6, IL-8, IL-12 and TNF- was performed by LUMINEX
illipex kits.
mage  assessment
ET–CT scans were acquired using a Gemini PET–CT scan-
er (Philips) after at least a 6-h fasting period. Capillary
lucose levels were checked before scans and no one pre-
ented levels above 200 mg/dL prior to 18F-FDG administration.
mage  acquisition was performed 60 min  after the infusion 6;5 6(4):299–308 301
of 0.154 millicurie (mCi)/kg of 18F-FDG and participants were
scanned from the skull to proximal thighs. Firstly, CT images
were obtained without the infusion of intravenous contrast
using the following parameters: 120 kV, 120 mAs, 0.75 s per
rotation, pitch 1.5, 5 mm slice thickness and a 3 mm recon-
struction interval. Then PET scan was acquired during 2 min
and 15 s at each bed position in a total of 11 bed positions. PET-
control subjects had undergone the same protocol and their
scans were retrieved from the archive. All PET–CT scans were
performed at AC Camargo Hospital and images were evalu-
ated by a radiologist (PNVP) and a nuclear medicine physician
(ICGT) who were unaware of clinical and laboratory assess-
ments of TA patients.
A semi-quantitative assessment of 18F-FDG uptake was
done at using the standard uptake value (SUV). The SUV
was calculated dividing the maximum tissue concentration
by the total injected dose of 18F-FDG per body weight. The
region of interest (ROI) was manually placed on artery walls of
the following sites: vertebral, internal carotid, subclavian and
common carotid arteries, pulmonary artery, brachiocephalic
trunk, aortic arch, ascending, descending and abdominal
aorta, celiac trunk, superior and inferior mesenteric arteries,
renal and iliac arteries. The highest value of SUV  found in each
artery was recorded and only the highest value on the whole
PET–CT scan (SUVmax) was used for statistical analysis.
Statistical  analysis
Statistical analysis was performed with the software Statisti-
cal Package for the Social Sciences (SPSS) version 17.0 (Chicago,
IL). Categorical data was presented as total number and per-
centage, and numerical data as median (range) or mean
(standard deviation) as appropriate. The Shapiro–Wilk test
was used to test the normality of continuous variables. Com-
parisons regarding numerical variables were performed with
Mann–Whitney U test or Student’s t test for two groups or with
Kruskal–Wallis test or one-way ANOVA test for three or more
groups. The Mann–Whitney U test with Bonferroni’s correction
was used as a post hoc test. Values of p < 0.05 were consid-
ered signiﬁcant while p values between 0.10 and 0.05 were
considered as statistical tendency.
SUVmax values for the diagnosis of disease activity was
evaluated by the ROC (receiver operating characteristic) curve
and the Youden index was used to assess the best cutoff val-
ues. Results of the ROC curve were expressed in area under
the curve, 95% conﬁdence interval (95% CI), positive predic-
tive value, negative predictive value, accuracy, sensitivity and
speciﬁcity for cutoff points of SUVmax. Correlations between
numerical variables were performed by Spearman’s test. The
presence of active disease in TA determined by the cutoff of
SUVmax was compared to disease activity determined by clini-
cal evaluation using Fisher’s exact test. Statistical signiﬁcance
was considered for p < 0.05.
ResultsPatients  and  controls
Thirty-six TA patients were evaluated in this study, 14 patients
(38.9%) had active disease while 11 (30.6%) patients were
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Table 1 – Demographic and disease features of TA patients evaluated in this study.
Variables Active disease (n = 14) Inactive disease (n = 11) Possible active disease (n = 11) p
Age, years 35.0 (22.0–54.0) 32.0 (24.0–68.0) 32.0 (21.0–56.0) 0.818
Females, n (%) 14 (100.0) 9 (81.8) 10 (90.9) 0.262
Time since ﬁrst TA symptoms, months 72.0 (24.0–216.0) 85.0 (23.0–372.0) 118.0 (9.0–207.0) 0.800
Time since diagnosis, months 45.5 (2.0–216.0) 66.0 (17.0–292.0) 58.0 (1.0–240.0) 0.628
ESR, mm/h 20.00 (5.00–115.00) 11.00 (1.00–26.00) 26.00 (7.00–70.00) 0.059
Serum CRP levels, mg/dL 18.17 (0.10–99.05) 1.53 (0.17–7.77) 78.13 (8.16–91.89) <0.0001
d ran
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
Data are presented as mean and standard deviation or as median an
considered with inactive disease and 11 (30.6%) had possi-
ble active disease. Table 1 describes demographic features,
time since the onset of symptoms attributable to TA, time
since diagnosis and acute phase reactants in subgroups of
TA patients. Patients with active disease had higher ESR and
serum CRP levels than patients with inactive disease. TA
patients with possible active disease had signiﬁcantly higher
serum CRP levels than patients in remission and a trend to
have higher ESR than patients in remission (Table 1). At the
time of assessment, 21 patients were on steroids and immu-
nosuppressive agents, three patients only on steroids, six
were treated only with an immunosuppressive agent and six
other patients were not receiving any therapy for TA. The
median prednisone daily dose was 12.5 mg  (5.62–27.50). The
following immunosuppressive agents were used by patients:
methotrexate (50.0%), mycophenolate sodium (11.1%), aza-
thioprine (8.3%), and cyclophosphamide (5.6%). Only one
patient used etanercept.
The lab-control group comprised 33 women and 3 men,
with a median age of 34.0 (20–68) years. All lab-controls did not
present any medical condition and were not under any med-
ical therapy. The PET-control group consisted of six healthy
individuals (four women, two men) with median age of 32.5
(28–45) years.
Cytokines  and  metalloproteinases
Table 2 shows serum levels of cytokines and MMPs in TA
patients and lab-controls. TA patients presented higher IL-6
levels (p < 0.001) and higher serum MMP-3 levels (p < 0.001) and
a tendency for higher TNF- levels (p = 0.069) than lab-controls.
No signiﬁcant differences were found regarding serum
Table 2 – Serum levels of cytokines and metalloproteases in TA
Markers TA patients (n = 36) 
IL-2, pg/mL 0.36 (0.00–23.38) 
IL-6, pg/mL 7.55 (0.17–76.22) 
IL-8, pg/mL 4.83 (1.88–17.92) 
IL-12, pg/mL 0.00 (0.00–46.39) 
IL-18, pg/mL 151.71 (0.00–463.26) 
TNF-, pg/mL 5.64 (1.91–15.28) 
MMP-3, ng/mL 27.00 (6.00–102.70) 
MMP-9, ng/mL 495.55 (183.70–2338.80) 
IL, interleukin; MMP, matrix metalloproteinase; TNF, tumor necrosis factor
Continuous data are presented as median and range or as mean and stan
a Statistically signiﬁcant values.ge.
levels of IL-2, IL-8, IL-12, IL-18 and MMP-9 when comparing
TA patients and lab-controls (Table 2).
Serum cytokine and MMPs levels in TA patients with active
disease, patients with inactive disease and patients with pos-
sible active disease are shown in Table 3. Serum IL-6 levels
were higher in patients with active disease and in patients
with possible active disease compared to with patients with
inactive disease (p < 0.0001) (Fig. 1). Although a tendency for
differences was found regarding serum TNF and IL-18 levels
among TA subgroups, when those subgroups were analyzed
separately, TA patients with active disease had signiﬁcantly
higher serum TNF levels than patients with inactive disease
(p = 0.049) while patients with possible active disease pre-
sented higher serum IL-18 levels than patients with inactive
disease (p = 0.046).
Correlations  among  inﬂammatory  markers  in  TA  patients
IL-6 levels correlated with ESR (rho = 0.475; p = 0.005) and with
CRP levels (rho = 0.673; p < 0.001). CRP levels and ESR values
(rho = 0.585; p < 0.001) were signiﬁcantly correlated as well.
TNF- levels correlated with IL-6 (rho = 0.365; p = 0.029), IL-8
(rho = 0.346; p = 0.039), as well as with CRP levels (rho = 0.370;
p = 0.026). Furthermore, serum IL-2 and IL-12 levels were corre-
lated (rho = 0.529, p = 0.001). No correlations were found among
other cytokines and MMPs.
Medical  therapy,  cytokines,  metalloproteinases  and  acute
phase  reactants
MMP-3 levels were higher in TA patients using steroids
than in those without steroids (45.05 ± 26.96 ng/mL vs.
 patients and controls.
Lab-controls (n = 36) p
0.25 (0.00–21.87) 0.710
1.74 (0.17–16.21) <0.0001a
4.49 (2.02–22.02) 0.327
0.00 (0.00–11.97) 0.908
121.63 (0.00–745.22) 0.130
4.26 (1.41–12.89) 0.056
12.05 (4.30–75.50) <0.0001a
452.15 (221.20–2044.00) 0.457
.
dard deviation.
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Table 3 – Serum levels of cytokines and metalloproteases in TA patients with active disease, inactive disease and with
possible active disease.
Variables Active disease (n = 14) Inactive disease (n = 11) Possible active disease (n = 11) p
TNF,  pg/mL 5.93 (3.84–10.71) 4.16 (1.91–15.28) 6.76 (3.69–9.23) 0.079
IL-2, pg/mL 0.19 (0.00–1.57) 1.12(0.00–12.04) 0.44 (0.00–23.38) 0.354
IL-6, pg/mL 9.15 (0.65–76.22) 2.48 (0.17–10.80) 8.48 (1.25–37.56) 0.003a
IL-8, pg/mL 5.47 (2.83–17.92) 4.53 (1.88–10.56) 4.61 (2.74–8.82) 0.368
IL-12, pg/mL 0.00 (0.00–2.22) 0.00 (0.00–12.56) 0.00 (0.00–46.39) 0.587
IL-18, pg/mL 183.58 ± 129.05 119.96 ± 57.98 246.20 ± 147.29 0.059
MMP3, ng/mL 22.40 (6.00–94.90) 26.30 (9.30–102.70) 31.10 (7.10–84.90) 0.682
MMP9, ng/mL 515.10 (208.40–2338.80) 424.20 (183.70–1422.50) 491.30 (274.40–1160.40) 0.547
IL, interleukin; MMP, matrix metalloproteinase; TNF, tumor necrosis factor.
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3.11 ± 6.36 ng/mL; p < 0.001) and a positive correlation was
bserved between MMP-3 levels and daily prednisone dose
rho = 0.463; p = 0.023) (Fig. 2). No associations were found
mong steroids use, daily prednisone dose, immunosuppress-
ve therapy and levels of MMP-9, cytokines or acute phase
eactants (data not shown).
ET–CT  scan  and  biomarkers
edian SUVmax values were higher in TA patients than in PET-
ontrols [1.57 (0.87–3.04) vs. 0.99 (0.67–1.23); p = 0.001] and in
atients with active disease compared with those in remission
1.97 (1.19–3.04) vs. 1.19 (0.87–2.59); p = 0.015]. However, no sig-
iﬁcant differences regarding SUVmax could be found between
A patients with active disease and those with possible
ctive disease [1.97 (1.19–3.04) vs. 1.58 (1.00–2.72); p = 0.324] or
etween patients with possible active disease and those with
nactive disease [1.58 (1.00–2.72) vs. 1.19 (0.87–2.59); p = 0.212].
urthermore, patients with inactive disease presented higher
Possible active diseaseInactive diseaseActive disease
.00
20.00
40.00
p=0.001
p=0.584o
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o
o
p=0.008
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l
60.00
80.00
ig. 1 – IL-6 levels in patients with active disease, inactive
isease and possible active disease. Serum IL-6 levels were
igniﬁcantly higher in patients with active disease and in
atients with possible disease activity than in patients
ith inactive disease. No signiﬁcant differences could be
ound between TA patients with active disease and patients
ith possible active disease.ard deviation.
SUVmax values than PET-controls [1.19 (0.87–2.59) vs. 0.99
(0.67–1.23); p = 0.049]. Fig. 3 illustrates the PET–CT ﬁndings in a
TA patient with active disease.
TA patients on immunosuppressive therapy presented
lower median SUVmax values than patients without those
agents [1.41 (0.87–3.04) vs. 2.57 (0.96–3.00); p = 0.044]. How-
ever, no differences in median SUVmax values were found
in patients with and without steroids [1.48 (0.87–3.04) vs.
2.14 (0.96–3.00); p = 0.127] as well as no correlation was found
between SUVmax and daily prednisone dose (rho = 0.233;
p = 0.274). Moreover, no correlations were found between
SUVmax values and ESR (rho = 0.081; p = 0.647) or CRP levels
(rho = 0.139; p = 0.419) and between SUVmax values and lev-
els of any cytokine or MMPs evaluated in this study (data not
shown).
ROC curve analysis showed the value of SUVmax as a pre-
dictor of active disease in TA (AUC = 0.703; 95% CI = 0.534–0.832;
p = 0.043). The best cutoff points obtained for SUVmax val-
ues (with their respective sensitivity and speciﬁcity) were:
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Fig. 2 – Correlation between serum levels of MMP-3 and
prednisone daily dose. A signiﬁcant correlation was found
between serum MMP-3 levels and daily prednisone dose
(rho = 0.463; p = 0.023).
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Fig. 3 – Representative PET–CT scan images from a patient with Takayasu arteritis and active disease.
PET–CT scan images of a 32-years-old female patient with clinically active disease: (A) fusion image in coronal
reconstruction with 18F-FDG uptake in ascending aorta, (B) images of PET scan in coronal plane with 18F-FDG uptake in the
abdominal and ascending aorta; (C) fusion image in axial section showing 18F-FDG uptake in ascending aorta and right
-FDGpulmonary artery, (D) fusion image in axial section with 18F
1.23, (93% and 45%), 1.29 (86% and 50%) and 1.83 (57% and
73%). More  TA patients presenting active disease based on NIH
criteria had SUVmax ≥ 1.3 on arterial walls when compared to
those with SUVmax < 1.3 (p = 0.039) (Table 4). This cutoff value
yielded a positive predictive value of 52.0%, a negative predic-
tive value of 78% and an accuracy of 63.8% for active disease in
TA. Patients with SUVmax values ≥1.3 presented higher TNF-
 (p = 0.015) and IL-6 levels (p = 0.036) in comparison to those
with SUVmax value <1.3 and lab-controls (Fig. 4A and B). No sig-
niﬁcant differences were found regarding levels of IL-2, IL-8,
Table 4 – Comparison of disease activity parameters, cytokines
SUVmax cutoff value of 1.3.
Variables SUVmax ≥ 1.3 (n = 23) 
Active disease, n (%) 12 (52.2) 
ESR, mm/h 19.00 (5.00–115.00) 
CRP, mg/dL 24.56 (0.10–99.05) 
TNF, pg/mL 6.76 (3.56–15.28) 
IL-2, pg/mL 0.44 (0.00–23.38) 
IL-6, pg/mL 8.48 (0.43–76.22) 
IL-8, pg/mL 5.15 (1.88–17.92) 
IL-12, pg/mL 0.00 (0.00–46.39) 
IL18, pg/mL 164.60  (0.00–424.01) 
MMP-3, ng/mL 26.90 (6.00–94.90) 
MMP-9, ng/mL 499.80 (183.70–2338.80) 
CRP, C-reactive protein, ESR, erythrocyte sedimentation rate; IL, interleuki
tumor necrosis factor.
a Statistically signiﬁcant values. Continuous data are presented as medi uptake in the abdominal aorta.
IL-12, IL-18, MMP-3, MMP-9, ESR and CRP regarding the SUVmax
cutoff value of 1.3 (Table 4).
DiscussionThis is the ﬁrst study evaluating the majority of biomarkers
of inﬂammatory activity already reported in the literature,
including several cytokines and MMPs as well as 18F-FDG
uptake in large arteries on PET–CT scan in TA patients. TA
 and matrix metalloproteinases in TA patients based on
SUVmax < 1.3 (n = 13) p
2 (15.4) 0.039a
14.00 (1.00–70.00) 0.139
5.23 (0.17–82.34) 0.096
4.37 (1.91–9.23) 0.015a
0.05 (0.00–8.50) 0.484
4.46 (0.17–37.56) 0.036a
4.53 (2.16–10.56) 0.553
0.00 (0.00–5.06) 0.130
132.05 (60.95–463.26) 0.987
27.10 (7.10–102-70) 0.542
461.60 (283.20–1442.40) 0.564
n; MMP, matrix metalloproteinase; SUV, standard uptake value; TNF,
an and range.
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Fig. 4 – Serum TNF and IL-6 levels in patients with
SUVmax ≥ 1.3, patients with SUVmax < 1.3 and lab-controls.
Serum TNF (A) and IL-6 (B) levels were  signiﬁcantly higher
in TA patients presenting SUVmax ≥ 1.3 compared to
patients with SUVmax < 1.3 and lab-controls. No difference
could be found regarding serum TNF and IL-6 levels
between patients with SUVmax < 1.3 and lab-controls.
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disease extent index in TA (DEI.TAK) and physician’s globalatients presented higher SUVmax values of 18F-FDG uptake
n large arteries by PET–CT scans and higher serum levels
f IL-6 and MMP-3 than controls. Moreover, SUVmax values of
8F-FDG uptake on large arteries, serum IL-6 and TNF lev-
ls were higher in TA patients presenting active disease when
ompared to those considered with inactive disease. Patients
ith possible active disease (i.e. only high acute phase reac-
ants without signs and symptoms of active TA) present higher
erum IL-6 and IL-18 levels than patients with inactive disease.
owever, no signiﬁcant differences were observed regarding
UVmax values in patients with possible active disease com-
ared to those with active disease and those with inactive
isease.
Although being a rare disorder, TA often causes high mor-
idity due to the progression of vascular lesions, and to
he lack of reliable parameters to detect disease activity to
llow an efﬁcacious intervention. Studies evaluating surrogate 6;5 6(4):299–308 305
markers and imaging methods to assess disease activity in TA
patients have provided inconsistent results. The reasons for
this include the lack of a gold standard to detect disease activ-
ity and the inclusion of small number of TA patients in various
studies.
Corroborating previous studies5,6 we found association of
serum IL-6 levels with both the disease status and disease
activity in TA. Differently from the results of Park et al.,6 serum
TNF levels were higher in patients with active disease than
those in remission but the difference showed only a tendency
to be higher among TA patients than in lab-controls (p = 0.056).
Serum levels of other cytokines were not different between
TA patients and controls and they were not useful to differen-
tiate TA patients with active and inactive disease. Although,
a previous study had found an association between disease
activity and serum levels of IL-18 in TA patients,6 we  could
not ﬁnd signiﬁcant differences in IL-18 levels between patients
and controls, or between TA patients with active and inac-
tive disease. Indeed, we found higher serum IL-18 levels in TA
patients with possible active disease compared to controls and
this may indicate that those patients may present subclinical
inﬂammation. Similarly to Trypathy et al., we  found no differ-
ences in serum IL-2 levels between TA patients and controls.
Nevertheless, they observed a lower percentage of IL-2 produc-
ing CD3+ T-cells in patients with active disease in comparison
to patients with inactive disease and controls.14 The role of
IL-12 as a surrogate marker of disease activity in TA is still
controversial. In one study, similar levels of serum IL-12 were
found between patients and controls while in another study,
plasma IL-12 levels were higher in patients with active disease
in comparison to those with inactive disease and controls.6,15
In the present study, IL-12 levels were similar in TA patients
and controls and no association with disease activity could
be found. Although IL-8 levels were higher in TA patients than
in controls and associated with disease activity in one study,16
we could not ﬁnd any differences regarding IL-8 levels between
patients and controls.
In a single study, higher MMP-3 and MMP-9 levels were
associated with active disease in TA patients, with a subse-
quent decrease following disease control.7 In our study, only
MMP-3 levels were higher in patients than in controls but
no difference related to disease activity was found. MMP-
3 levels were higher among patients using steroids with a
positive correlation between MMP-3 levels and daily pred-
nisone dose. The association between steroid daily dose and
MMP-3 levels was also reported in patients with rheumatic
diseases,17 including a recent study in patients with TA.18
Sharif et al.19 found a 53% increase in pro-MMP-3 levels in
patients with rheumatoid arthritis using prednisone, even
amongst patients presenting a decrease in other inﬂamma-
tory parameters. However, the mechanism involved in MMP-3
elevation associated with steroids use is still unclear.
Initial studies with PET–CT scans evaluating disease
activity in TA showed promising results.10,20 More  recently,
Karapolat et al. evaluated the usefulness of PET–CT scans
to detect disease activity in TA using the NIH criteria, theassessment as clinical parameters. They found that PET–CT
scans had 100% sensitivity and 88.9% speciﬁcity with 66% of
positive predictive value and 100% negative predictive value
 o l . 2
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to detect active disease in TA.21 However, another study
has raised questions about the usefulness of this method,
since there is no SUV value deﬁned as normal for the ves-
sel wall.11 A meta-analysis including six studies found that
PET–CT scan had a moderate value to evaluate disease activ-
ity in TA. The pooled sensitivity and speciﬁcity were 70.1%
(95% CI: 58.6–80.0) and 77.2% (95% CI: 64.2–87.3), respectively.
Authors considered that PET–CT scan was not suitable to
be used as the sole method to evaluate disease activity in
TA but it may be additional value to current clinical assess-
ment. Heterogeneity among studies is a limitation of this
meta-analysis.22
Several studies have considered the SUV values useful
in the diagnosis and prognosis for cancers.23–25 Neverthe-
less, this imaging technique is still a matter of debate as
long as a large variability of SUV values has been observed
among several institutes, thus raising the need to calibrate
equipments and standardize parameters for data acquisi-
tion and processing in order to obtain comparable results.26
SUVmax values become more  reliable when used as param-
eters within the same institute, under the same technical
conditions, especially in the comparison of serial imaging
studies.
In this study, PET–CT scans were performed under fasting
conditions and capillary blood glucose was checked before 18F-
FDG administration to exclude the possibility of false-negative
results due to hyperglycemia. Although, the 18F-FDG in TA
might be taken up mostly by inﬂammatory cells in vessel
walls, the inﬂuence of blood glucose levels has not been still
established in this context.27 Rabkin et al.28 have described
false-negative results in patients with different types of cancer
when blood glucose exceeded 180 mg/dL, but not in patients
with infectious or inﬂammatory conditions.
Henes et al. studied the use of PET–CT in patients with large
vessel vasculitis, including three patients with TA and found
SUVmax values between 1.6 and 6.8 within arterial walls. In this
study, SUVmax values ranged from 2.5 to 5.8 in TA patients with
active disease. Among eight patients with surgically treated
solid tumors used as controls, SUVmax values ranged from 1.4
to 2.3.8
Another study evaluated PET–CT scans in 20 patients with
large vessel vasculitis including 3 patients with TA. The
SUVmax cutoff value of 1.78 had the best performance for the
diagnosis of a large vessel vasculitis with sensitivity and speci-
ﬁcity of, respectively, 65% and 80% by visual scale, and 90%
and 45% by the SUVmax. The control group was constituted by
patients treated for thyroid cancer.12
SUVmax values in the above-mentioned studies were
slightly higher than what we found for TA patients. Techni-
cal differences in PET–CT scan protocols may be a hurdle to
compare our results with different studies. Furthermore, our
study included only TA patients with a mean age of 36 years
whereas in the above-mentioned studies,8,12 most patients
had giant cell arteritis with a higher mean age (62 years).
Our control group consisted of healthy subjects, instead of
cancer patients. The inﬂuence of age in the increase of 18F-
FDG has been demonstrated in one retrospective study29 and
it may occur in part due to atherosclerosis. Indeed, this fact
might reduce PET–CT scans speciﬁcity in TA patients, since the
prevalence of atherosclerosis is increased in those patients.30 0 1 6;5 6(4):299–308
Arnaud et al. found low sensitivity and speciﬁcity of PET–CT
scan to detect disease activity in TA patients. They did not
ﬁnd any association with either inﬂammatory markers or new
lesions on serial MRI angiographies. They used visual scale
and quantitative evaluation to assess 18F-FDG uptake and
found a strong correlation between both methods.11 In con-
trast, Lee et al. have also evaluated the PET–CT scans in TA
patients using the visual scale and SUV. They found an asso-
ciation between 18F-FDG uptake in vessel wall and disease
activity in both assessments.31
Using the SUVmax to measure 18F-FDG uptake, we  found
higher values of SUVmax in TA patients with active disease
compared to those with inactive disease. Hence in our study,
SUVmax seemed to be predictive of disease activity in TA.
Patients using immunosuppressive agents had lower arterial
SUVmax values comparing with those without these medica-
tions. This ﬁnding indicates a suppressive effect on vascular
inﬂammation brought by the use of these agents and adds
another argument in favor of the usefulness of PET–CT scans
for the detection of the vascular inﬂammation in TA. In line
with this ﬁnding, Lee et al.31 have described a decrease in
18F-FDG uptake during the follow-up of eight patients after
controlling disease activity with immunosuppressive treat-
ment.
We found SUVmax values similar to those found by
Kobayashi et al., despite technical differences in study pro-
tocols. The cutoff value of 1.3 was the same in both studies
and was based on the highest SUVmax value found in controls.
However, the sensitivity and speciﬁcity for detection of disease
activity were 86% and 50%, respectively, in our study, which
are lower than those found by these authors. This remarkable
difference may be due to different criteria used for clinical
evaluation in both studies. They considered clinical remission
only when patients were at least 2 years without steroid.10
Our study also analyzed the association between a cutoff
value of SUVmax and serum levels of cytokines and MMPs.
Patients with SUVmax ≥ 1.3 had higher levels of TNF- and IL-6.
We also found an association between SUVmax ≥ 1.3 and dis-
ease activity. The analysis of biomarkers using this SUVmax
cutoff value highlights the consistent results achieved from
clinical evaluation of disease activity in TA. The signiﬁcant
correlation between serum IL-6 levels and other inﬂammatory
markers indicates the consistency of these ﬁndings.
Main limitations of this study include the sample size,
the cross-sectional design and the lack of a gold standard to
evaluate inﬂammatory activity in TA, since even the widely
used NIH criteria have not been validated yet. Moreover, the
weakness of the NIH criteria is highlighted by the fact that
TA patients with high acute phase reactants who do not ful-
ﬁll the NIH criteria for active disease actually present higher
serum levels of IL-6 and IL-18 than TA patients considered with
inactive disease. Such patients should be followed up more
carefully in order to detect clinically signiﬁcant active disease
early. However, the low number of patients in the subgroups
of inactive patients and patients with possible active disease
may have impaired comparisons among groups and assump-caution.
Our results suggest that the intensity of 18F-FDG uptake
in arterial wall may reﬂect the intensity of the inﬂammatory
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rocess and that PET–CT scan seems to be a useful method
o detect disease activity in TA, especially to exclude active
isease in doubtful cases. A prospective study with a long
erm follow-up would be necessary to observe changes in the
UVmax values after treatment or even to detect the devel-
pment of new vascular lesions (e.g. vascular stenosis or
neurysms) in sites presenting high 18F-FDG uptake. IL-6 also
ppears to be a promising parameter of disease activity in TA
hat should be assessed in a longitudinal study as well. The rel-
vance of IL-6 resides in the fact that it can also be a potential
herapeutic target in TA.32
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